secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202506
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q1 revenue $191.2M (+57% YoY); Auvelity approved for Alzheimer's agitation
--------------------------------------------------------------------------------

- Total net product revenue $191.2M (+57% YoY); Auvelity $153.2M (+59%), Sunosi $33.9M (+34%), Symbravo $4.1M.
- Net loss $64.5M ($1.26/share) vs $59.4M ($1.22/share) YoY; cash $305.1M at March 31, 2026.
- FDA approved Auvelity for agitation in Alzheimer's disease (April 2026); full commercial launch expected June 2026.
- NDA submitted for AXS-12 (cataplexy in narcolepsy); pipeline expanded with AXS-20 (balipodect) for schizophrenia/Tourette.
- Cash guidance: current resources sufficient to fund operations into cash flow positivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/0001193125-26-202506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer